Literatur
- 1
Adler A, Gillon G, Lurie H. et al .
Active specific immunotherapy of renal
cell carcinoma patients: a prospective randomized study of hormono-immuno-
versus hormonotherapy. Preliminary report on immunological and clinical
aspects.
J Biol Response Mod.
1987;
6
610-624
- 2
Anton P, Kirchner H, Jonas U, Atzpodien J.
Prospektiv
randomisierter Vergleich der kombinierten Immunchemotherapie mit
alpha-INF, IL-2 und 5-Fluorouracil mit Tamoxifen als Monotherapie.
Urologe [A].
1997;
37
42
(Suppl 1/97)
- 3
Atzpodien J, Kirchner H, Poliwoda H.
Interleukin-2-haltige
ambulante Therapie des metastasierenden Nierenzellkarzinoms.
Med
Klin.
1996;
91
38-43
- 4
Brinkamnn O A, Lümmen G, Luboldt H J, Hertle L, Rübben H.
Interferon-(,
Interleukin-2 und 5-Fluorouracil versus Mistellektin beim metastasierten
Nierenzellkarzinom.
Urologe [A].
1999;
38
77
(Suppl 1)
- 5
Chang A E, Yoshizawa H, Sakai K, Cameron M J, Sondak V K, Shu S.
Clinical observations on
adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily
sensitized to tumor in vitro.
Cancer Res.
1993;
53
1043-1050
- 6
Chang A E, Aruga A, Cameron M J. et al .
Adoptive immunotherapy with vaccine-primed
lymph node cells secondarily activated with anti-CD3 and interleukin-2.
J
Clin Oncol.
1997;
15
796-807
- 7
Änderung der BUB-Richtlinien
vom 10. April 2000.
Deutsches Ärzteblatt.
2000;
97
B-2063
- 8
Dutcher J, Atkins M, Fisher R. et al .
IL-2 based therapy in metastatic renal
cell cancer.
Proc Am Soc Clin Oncol.
1997;
16
327
- 9
Elias L, Binder M, Mangalik A. et al .
Pilot
trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous
interferon-alpha for advanced renal cell carcinoma.
Am
J Clin Oncol.
1999;
22
156-161
- 10
Ellerhorst J A, Sella A, Amato R J. et al .
Phase 2 trial of 5-Fluorouracil, interferon-alpha
and continous infusion interleukin-2 for patients with metastatic
renal cell carcinoma.
Cancer.
1997;
80
2128-2132
- 11
Fenton R G, Steis R G, Madara K. et al .
A phase I randomized study of subcutaneous
adjuvant IL-2 in combination with an autologous tumor vaccine in
patients with advanced renal cell carcinoma.
J Immunother
Emphasis Tumor Immunol.
1996;
19
364-374
- 12
Figlin R A.
Renal
cell carcinoma: management of advanced disease.
J Urol.
1999;
161
381-387
- 13
Fowler J E.
Failure
of immunotherapy for metastatic renal cell carcinoma.
J
Urol.
1986;
135
22-25
- 14
Galligioni E, Quaia M, Merlo A. et
al .
Adjuvant immunotherapy treatment of renal carcinoma
patients with autologous tumor cells and bacillus Calmette-Guerin:
five-year results of a prospective randomized study.
Cancer.
1996;
77
2560-2566
- 15
Gitlitz B J, Dolan N, Pierce W. et al .
Fluoropyrimidines plus interleukin-2 and
interferon alpha in the treatment of metastatic renal cell carcinoma.
Proc
Am Soc Clin Oncol.
1996;
15
248
- 16
Harris D T.
Hormonal
therapy and chemotherapy of renal cell carcinoma.
Semin
Oncol.
1983;
10
422-4309
- 17
Heinzer H, Huland E, Aalamanian M, Huland H.
Behandlung des pulmonal
metastasierten Nierenzellkarzinoms mit inhalativem Interleukin-2.
Urologe [A].
1999;
38
466-473
- 18
Hofmockel W, Langer W, Theiss M, Gruss A, Frohmüller H GW.
Immunochemotherapy
for metastatic renal cell carcinoma using a regimen of interleukin-2,
interferon-( and 5-Fluorouracil.
J Urol.
1996;
156
18-21
- 19
Huguenin P U, Kieser S, Glanzmann C, Capaul R, Lutolf U M.
Radiotherapy
for metastatic carcinomas of the kidney or melanomas: an analysis
using palliative endpoints.
Int J Radiat Oncol Biol Phys.
1998;
41
401-405
- 20
Joffe J K, Banks R E, Forbes M A. et al .
A phase II study of interferon-(, interleukin-2
and 5-fluorouracil in advanced renal cell carcinoma: clinical data
and laboratory evidence of protease activation.
Brit J
Urol.
1996;
77
638-649
- 21
Jones M, Philip T, Palmer P. et al .
The impact
of interleukin-2 on servival in renal cancer: a multivariate analysis.
Cancer
Biother.
1993;
8
75-288
- 22
Klippel K F, Jacobi G H, Schulte-Wissermann H.
Aktive
Immuntherapie beim metastasierenden Hypernephrom.
Akt
Urol.
1981;
12
161-165
- 23
Kugler A, Seseke F, Thelen P. et al .
Autologous and allogenic hybrid cell vaccine
in patients with metastatic renal cell carcinoma.
Br J
Urol.
1998;
82
487-493
- 24
Kugler A, Stuhler G, Walden P. et al .
Regression of human metastatic renal cell
carcinoma after vaccination with tumor cell-dendritic cell hybrids.
Nat
Med.
2000;
6
332-336
- 25
Kurth K H, Merquet R, Zwartendijk J, Warnaar S O.
Autologous
anticancer antigen preparation for specific immunotherapy in advanced renal
carcinoma.
Eur Urol.
1987;
13
103-109
- 26
Lokich J.
Spontaneus
regression of metastatic renal cancer. Case report and literature
review.
Am J Clin Oncol.
1997;
20
416-418
- 27
Lopez H änninen
E, Kirchner H, Atzpodien J.
Interleukin-2
based home therapy of metastatic renal cell carcinoma: risks and
benefits in 215 consecutive single institution patients.
J
Urol.
1996;
155
19-25
- 28
McCune C S, O`Donnel R W, Marquis D M, Sahasrabudhe D M.
Renal cell
carcinoma treated by vaccines for active specific immunotherapy:
correlation of survival with skin testing by autologous tumor cells.
Cancer
Immunol Immunother.
1990;
32
62-66
- 29
Medical Research Council
Renal Cancer Collaborators .
Interferon-alpha and survival
in metastatic renal carcinoma: early results of a randomised controlled
trial.
Lancet.
1999;
353
14-17
- 30
Mickisch G H, Roehrich K, Koessig J, Forster S, Tschada R K, Alken P M.
Mechanisms and
modulation of multidrug resistance in primary renal cell carcinoma.
J
Urol.
1990;
144
755-759
- 31
Mickisch G H, Garin A, Madej M.
Tumor
nephrectomy plus interferon alpha is superior to interferon alpha
alone in metastatic renal cell carcinoma.
J Urol.
2000;
163
176
(Suppl)
- 32
Neidhart J A, Murpy S G, Hennik L A, Wise H A.
Active specific
immunotherapy of stage IV renal carcinoma with aggregated tumor
antigen adjuvant.
Cancer.
1980;
46
1128-1134
- 33
Olencki T, Bukowski R M, Budd G T. et al .
Phase I/II trial of simultaneously
administered rIL-2/rHuIFN and 5-FU in patients with metastatic
renal cell carcinoma.
Proc Am Soc Clin Oncol.
1996;
15
263
- 34
Pizzocaro G, Piva L, Costa A. et
al .
Adjuvant interferon to radical nephrectomy in Robson`s
stage II and III renal cell cancer, a multicenter randomized study
with some biological evaluations.
Proc Am Soc Clin Oncol.
1997;
16
318A
- 35
Porzsolt F.
Adjuvant
therapy of renal cell cancer with interferon alpha-2a.
Proc
Am Soc Clin Oncol.
1992;
11
202
- 36
Pyrhönen S, Salminen E, Ruutu M. et al .
Prospective randomized trial of interferon
alpha-2a plus vinblastine versus vinblastine alone in patients with
advanced renal cell cancer.
J Clin Oncol.
1999;
17
2859-2867
- 37
Rauschmeier H A.
Immunotherapy
of metastatic renal cancer.
Semin Surg Oncol.
1988;
4
169-173
- 38
Ravaud A, Audhuy B, Gomez F. et al. Groupe Francais d’Immunotherapie .
Subcutaneous
interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil
in metastatic renal cell carcinoma: a multicenter phase II trial.
J
Clin Oncol.
1998;
16
2728-2732
- 39
Rieser C, Ramoner R, Höltl L. et al .
Mature dendritic cells induce T-helper
type-1-dominant immune responses in patients with metastatic renal
cell carcinoma.
Urol Int.
1999;
63
151-159
- 40
Rosenberg S A, Lotze M T, Muul L M. et al .
A progress report on the treatment of 157
patients with advanced cancer using lymphokine-activated killer
cells and interleukin-2 or high dose interleukin-2 alone.
N
Engl J Med.
1987;
316
889-897
- 41
Samland D, Steinbach F, Reiher F, Schmidt U, Gruss A, Allhoff E P.
Results of
immunochemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil
in the treatment of metastatic renal cell cancer.
Eur
Urol.
1999;
35
204-209
- 42
Schärfe T, Müller S, Riedmiller H, Jacobi G H, Hohenfellner R.
Immunotherapy
of metastasizing renal cell carcinoma.
Urol Int.
1989;
44
1-4
- 43
Sella A, Zukiwaki A, Robinson E. et al .
Interleukin-2
with interferon-a and 5-fluorouracil in patients with metastatic
renal cell carcinoma.
Proc Am Soc Clin Oncol.
1994;
13
237
- 44
Simons J W, Jaffee E M, Weber C E. et al .
Bioactivity of autologous irradiated renal
cell carcinoma vaccines generated by ex vivo granulocyte-macrophage
colony-stimulating factor gene transfer.
Cancer Res.
1997;
57
1537-1546
- 45
Tallberg T, Tykkä H, Mahlberg K. et al .
Active Specific Immunotherapy with Supportive
Measures in the Treatment of Palliatively Nephrectomized Renal Adenocarcinoma
Patients.
Eur Urol.
1985;
11
233-243
- 46
Tallberg T, Tykkä H.
Specific active
immunotherapy in advanced renal cell carcinoma: a clinical longterm
follow-up study.
World J Urol.
1986;
3
234-244
- 47
Tourani J M, Pfister C, Berdah J F. et al. Subcutaneous Administration Propeukin Program
Cooperative
Group .
Outpatient treatment with subcutaneous interleukin-2
and interferon alfa administration in combination with fluorouracil
in patients with metastatic renal cell carcinoma: results of a sequential
nonrandomized phase II study.
J Clin Oncol.
1998;
16
2505-2513
- 48
Trump D L, Elson P, Propert K. et al .
Randomized, controlled trial of adjuvant
therapy with lymphoblastoid interferon (L-IFN) in resected, high
risk renal cell carcinoma.
Proc Am Soc Clin Oncol.
1996;
15
253
- 49
van Herpen C M, Jansen R L, Kruit W H. et al .
Immunochemotherapy with interleukin-2,
interferon-alpha and 5-fluorouracil for progressive metastatic renal
cell carcinoma: a multicenter phase II study. Dutch Immunotherapy
Working Party.
Br J Cancer.
2000;
82
772-776
Korrespondenz
Dr. med. Thomas Steiner
Klinik und Poliklinik für Urologie, Friedrich-Schiller-Universität
Jena
Lessingstraße 1
07743 Jena
Telefon: 03641 935002
Fax: 03641/935003
eMail: thomas.steiner@med.uni-jena.de
